Elsevier

Obstetrics & Gynecology

Volume 88, Issue 3, September 1996, Pages 437-442
Obstetrics & Gynecology

Hot flushes, menstrual status, and hormone levels in a population-based sample of midlife women

https://doi.org/10.1016/0029-7844(96)00196-2Get rights and content

Objective:

To determine the frequency of hot flushes in a population sample of 453 pre-, peri-, and postmenopausal women (aged 48–59 years), and to investigate the relationship of hot-flush reporting with menstrual status, serum levels of estradiol (E2), inhibin, and FSH, history of premenstrual complaints, and physical and life-style factors.

Methods:

We used a population-based sample. Interviews were conducted in the women's homes.

Results:

Frequency of hot-flush reporting was associated with menstrual status (P < .001). Twenty-nine percent of women who had more than 3 and less than 12 months of amenorrhea, and 37% of postmenopausal women experienced hot flushes several times a day. In total, 13% of premenopausal women, 37% of perimenopausal women, 62% of postmenopausal women, and 15% of women on hormone therapy reported having had at least one hot flush in the previous 2 weeks. Follicle-stimulating hormone levels were higher in women who experienced hot flushes at least once a day or more (P < .001); E2 levels were higher in women experiencing one or no hot flushes per week (P < .001). The women in the perimenopausal group who experienced hot flushes had higher FSH levels (P = .008) and were more likely to have reported premenstrual complaints at the first interview 3 years earlier (P = .03). In the postmenopausal group, there was no significant difference with any of the variables studied between the women who were experiencing hot flushes and those who were not.

Conclusion:

Reporting of hot flushes is greatest 3 months or more after the final menstrual period. The frequency of hot flushes is associated with increasing FSH, decreasing E2, and a history of premenstrual complaints.

References (19)

There are more references available in the full text version of this article.

Cited by (146)

  • Are serum estrogen concentrations associated with menopausal symptom bother among postmenopausal women? Baseline results from two MsFLASH clinical trials

    2022, Maturitas
    Citation Excerpt :

    In a study of perimenopausal women aged 40–59 years living in the UK or Bangladesh, E2 concentration was not associated with experiencing hot flushes in the past 2 weeks [23]. In the Melbourne Women's Midlife Health Project (women aged 48–59) lower serum E2 concentration was associated with higher odds of having any VMS in the past two weeks before adjustment for covariates, but no significant association among either peri- or post-menopausal women after adjustment for covariates [24]. Variations among the studies regarding which covariates were included in statistical models, ages, and menopausal transition stage of participants (peri- vs. post-menopausal), wording of questions regarding symptoms, VMS characterization in statistical models, and E2 and E1 assays may explain why some studies found associations between serum E2 concentration and VMS, and others did not.

  • Vasomotor menopausal symptoms and cardiovascular disease risk in midlife: A longitudinal study

    2020, Maturitas
    Citation Excerpt :

    Estrogen decline is often accompanied by the development of VMS and women experiencing severe VMS often use MHT to reduce the symptoms. The decline in estrogen is also suggested to be associated with an increased CVD risk [19,20], which might be counteracted by MHT use. However, recent meta-analyses of clinical trials with MHT found no associations for cardiac or stroke mortality [21], or even an increased CHD risk [22].

  • Midlife Women’s Health

    2023, Women’s Healthcare in: Advanced Practice Nursing, Third Edition
View all citing articles on Scopus

This study was supported by grants from the Victorian Health Promotion Foundation, the Public Health Research Development Committee (PHRDC), the National Health and Medical Research Council (NHMRC), the Percy Baxter Trust, the H & L Hecht Trust, the Estate of the late Daniel Scott, ANZ and Perpetual Trustees.

View full text